Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim prophylaxis for chemotherapy-induced neutropenia in elderly patients with lymphoma
ChiCTR1900021514Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in lymphoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Incidence of febrile neutropenia in each chemotherapy cycle. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
lymphoma
Beyond the preview
Go deeper on ChiCTR1900021514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021514.